



Programme



Welcome and introduction

Ross Soo (Chair)

National University Cancer Institute, Singapore



The role of *KRAS* as a molecular driver in advanced NSCLC and mCRC

Yasushi Yatabe

National Cancer Center Hospital, Tokyo, Japan



Changing the course for *KRAS*-mutated advanced NSCLC

Tony Mok

Chinese University of Hong Kong, Hong Kong



Changing the course for *KRAS*-mutated metastatic CRC

Tim Price

The Queen Elizabeth Hospital, Adelaide, Australia

LIVE Q&A and panel discussion

All, moderated by Ross Soo